PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF

(19)

(11)

EP 2 964 218 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	07.03.2018 Bulletin 2018/10

(45)	Mention of the grant of the patent:
	20.12.2017 Bulletin 2017/51

(21)	Application number: 14713588.3

(22)	Date of filing: 05.03.2014

(51)

International Patent Classification (IPC):

C07D 207/46^(2006.01)
C07D 223/04^(2006.01)
A61K 31/445^(2006.01)
A61P 13/12^(2006.01)
A61P 11/00^(2006.01)

C07D 211/94^(2006.01)
A61K 31/40^(2006.01)
A61K 31/55^(2006.01)
A61P 29/00^(2006.01)

(86)	International application number:
	PCT/IB2014/059451

(87)	International publication number:
	WO 2014/136059 (12.09.2014 Gazette 2014/37)

(54)	PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF PRODRUGS AUS MULTIFUNKTIONELLEN NITROXIDDERIVATEN UND VERWENDUNGEN DAVON PROMÉDICAMENTS DE DÉRIVÉS D'OXYDES D'AZOTE MULTIFONCTIONNELS ET LEURS UTILISATIONS

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

05.03.2013 US 201361772861 P

(43)	Date of publication of application:
	13.01.2016 Bulletin 2016/02

(73)	Proprietor: Salzman Group, Inc.
	West Tisbury, Massachusetts 02575 (US)

(72)	Inventors:
	SALZMAN, Andrew Lurie West Tisbury, Massachusetts 02575-1626 (US) JAGTAP, Prakash North Andover, Massachusetts 01845 (US) SOUTHAN, Garry John Swampscott, Massachusetts 01907 (US)

(74)	Representative: ABG Patentes, S.L.
	Avenida de Burgos, 16D Edificio Euromor 28036 Madrid 28036 Madrid (ES)

(56)

References cited: :

WO-A1-2011/092690
US-B1- 6 455 542

WO-A1-2013/005216

K. M. HUTTUNEN ET AL: "Prodrugs--from Serendipity to Rational Design", PHARMACOLOGICAL REVIEWS, vol. 63, no. 3, 1 September 2011 (2011-09-01), pages 750-771, XP055073805, ISSN: 0031-6997, DOI: 10.1124/pr.110.003459
RAUTIO JARKKO ET AL: "Prodrugs: design and clinical applications", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 7, no. 3, 1 March 2008 (2008-03-01), pages 255-270, XP002579584, ISSN: 1474-1784

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).